Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0003232,
umls-concept:C0009429,
umls-concept:C0021027,
umls-concept:C0021311,
umls-concept:C0086418,
umls-concept:C0205082,
umls-concept:C0220825,
umls-concept:C0302350,
umls-concept:C0302891,
umls-concept:C0302908,
umls-concept:C0543467,
umls-concept:C0556895,
umls-concept:C1521738,
umls-concept:C1521827
|
pubmed:issue |
1
|
pubmed:dateCreated |
1990-6-8
|
pubmed:abstractText |
In a nationwide study conducted in 11 surgical institutions of C-425, a newly developed human native immunoglobulin liquid preparation for intravenous injection, was combined with conventional antibiotic treatment to investigate the efficacy and safety. A total of 47 patients with severe infections which had not symptomatically responded to 3-day or longer treatment with any antibiotics was included. Doctors in charge judged the efficacy of C-425 to be "excellent" in 3 patients, "good" in 13, "fair" in 15, and "poor" in 4. Thus, a total of 16 patients (45.7%) was judged to have responded to C-425 when the "excellent" and "good" responses were combined. The number responding was 31 (88.6%) when the "fair" cases were also included. Excluding 31 patients who did not meet the Committee's criteria, the Committee judged the efficacy of C-425 in a total of 16 patients; the efficacy was "excellent" in 2 patients, "good" in 4, "fair" in 9, and "poor" in 1. The number of responding patients was 6 (37.5%) of the 16 when the "excellent" and "good" cases were combined, and 15 (93.8%) when the "fair" cases were added. Bacteriological assessment was conducted in a total of 9 patients. Causative bacteria were eradicated in 3 patients, decreased in number in 1, replaced in 2, and persisted in 3. Thus, bacteriological efficacy was observed in 6 of the 9 patients (66.7%). Neither adverse reactions nor drug-related laboratory abnormalities were observed in the 47 patients.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0387-5911
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
64
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
54-64
|
pubmed:dateRevised |
2008-12-16
|
pubmed:meshHeading |
pubmed-meshheading:2186161-Adult,
pubmed-meshheading:2186161-Aged,
pubmed-meshheading:2186161-Aged, 80 and over,
pubmed-meshheading:2186161-Anti-Bacterial Agents,
pubmed-meshheading:2186161-Bacterial Infections,
pubmed-meshheading:2186161-Drug Therapy, Combination,
pubmed-meshheading:2186161-Female,
pubmed-meshheading:2186161-Humans,
pubmed-meshheading:2186161-Immunoglobulin G,
pubmed-meshheading:2186161-Injections, Intravenous,
pubmed-meshheading:2186161-Male,
pubmed-meshheading:2186161-Middle Aged,
pubmed-meshheading:2186161-Multicenter Studies as Topic,
pubmed-meshheading:2186161-Neoplasms,
pubmed-meshheading:2186161-Peritoneal Diseases,
pubmed-meshheading:2186161-Respiratory Tract Infections,
pubmed-meshheading:2186161-Urinary Tract Infections
|
pubmed:year |
1990
|
pubmed:articleTitle |
[Therapeutic evaluation of combination therapy using C-425, human native immunoglobulin liquid preparation for i.v. administration, with antibiotics in severe infections in the field of surgery].
|
pubmed:affiliation |
Second Department of Surgery, Tokyo Medical and Dental University of Medicine.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Multicenter Study
|